{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T17:49:08Z","timestamp":1790617748705,"version":"4.1.0"},"reference-count":51,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,6,10]],"date-time":"2025-06-10T00:00:00Z","timestamp":1749513600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transplantation and Cellular Therapy"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1016\/j.jtct.2025.06.002","type":"journal-article","created":{"date-parts":[[2025,6,11]],"date-time":"2025-06-11T15:19:21Z","timestamp":1749655161000},"page":"494-504","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Clinical Practice Recommendations on the Role Of Allogeneic Hematopoietic Cell Transplantation and Chimeric Antigen Receptor T-Cell Therapy in Patients With Chronic Lymphocytic Leukemia on Behalf of the American Society for Transplantation and Cellular Therapy"],"prefix":"10.1016","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7394-5185","authenticated-orcid":false,"given":"Mohamed A.","family":"Kharfan-Dabaja","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1260-6694","authenticated-orcid":false,"given":"Ambuj","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Javier","family":"Pinilla-Ibarz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer R.","family":"Brown","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mazyar","family":"Shadman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1813-9812","authenticated-orcid":false,"given":"Farrukh T.","family":"Awan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2767-3830","authenticated-orcid":false,"given":"Saad S.","family":"Kenderian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tanya","family":"Siddiqi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8467-9257","authenticated-orcid":false,"given":"Jeremy S.","family":"Abramson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8359-0178","authenticated-orcid":false,"given":"Taha","family":"Al-Juhaishi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9581-2807","authenticated-orcid":false,"given":"Danielle M.","family":"Brander","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine C.","family":"Coombs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1677-7626","authenticated-orcid":false,"given":"Richard R.","family":"Furman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nitin","family":"Jain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadia","family":"Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nakhle S.","family":"Saba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3597-6295","authenticated-orcid":false,"given":"Jennifer M.","family":"Collins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amer","family":"Beitinjaneh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Deborah M.","family":"Stephens","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jennifer","family":"Woyach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5372-510X","authenticated-orcid":false,"given":"Mehdi","family":"Hamadani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"9","key":"10.1016\/j.jtct.2025.06.002_bib0001","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.3324\/haematol.10720","article-title":"Clonal evolution in chronic lymphocytic leukemia: acquisition of high-risk genomic aberrations associated with unmutated VH, resistance to therapy, and short survival","volume":"92","author":"Stilgenbauer","year":"2007","journal-title":"Haematologica"},{"issue":"6","key":"10.1016\/j.jtct.2025.06.002_bib0002","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.1182\/blood.V94.6.1840","article-title":"Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia","volume":"94","author":"Damle","year":"1999","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.jtct.2025.06.002_bib0003","doi-asserted-by":"crossref","first-page":"897","DOI":"10.1002\/cncr.23671","article-title":"Clinical and therapeutic implications of the mutational status of IgVH in patients with chronic lymphocytic leukemia","volume":"113","author":"Kharfan-Dabaja","year":"2008","journal-title":"Cancer"},{"issue":"26","key":"10.1016\/j.jtct.2025.06.002_bib0004","doi-asserted-by":"crossref","first-page":"1910","DOI":"10.1056\/NEJM200012283432602","article-title":"Genomic aberrations and survival in chronic lymphocytic leukemia","volume":"343","author":"Dohner","year":"2000","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.jtct.2025.06.002_bib0005","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1101\/gr.152132.112","article-title":"Transcriptome characterization by RNA sequencing identifies a major molecular and clinical subdivision in chronic lymphocytic leukemia","volume":"24","author":"Ferreira","year":"2014","journal-title":"Genome Res"},{"issue":"5","key":"10.1016\/j.jtct.2025.06.002_bib0006","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1038\/leu.2012.357","article-title":"NOTCH1 mutations identify a genetic subgroup of chronic lymphocytic leukemia patients with high risk of transformation and poor outcome","volume":"27","author":"Villamor","year":"2013","journal-title":"Leukemia"},{"issue":"4","key":"10.1016\/j.jtct.2025.06.002_bib0007","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1002\/cncr.29794","article-title":"beta2 -microglobulin normalization within 6 months of ibrutinib-based treatment is associated with superior progression-free survival in patients with chronic lymphocytic leukemia","volume":"122","author":"Thompson","year":"2016","journal-title":"Cancer"},{"issue":"1","key":"10.1016\/j.jtct.2025.06.002_bib0008","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1182\/blood-2014-02-556399","article-title":"Development of a comprehensive prognostic index for patients with chronic lymphocytic leukemia","volume":"124","author":"Pflug","year":"2014","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.jtct.2025.06.002_bib0009","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1016\/S1470-2045(16)30029-8","article-title":"An international prognostic index for patients with chronic lymphocytic leukaemia (CLL-IPI): a meta-analysis of individual patient data","volume":"17","author":"CLLIPIwg","year":"2016","journal-title":"Lancet Oncol"},{"issue":"2","key":"10.1016\/j.jtct.2025.06.002_bib0010","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.blre.2017.10.003","article-title":"Using prognostic models in CLL to personalize approach to clinical care: Are we there yet?","volume":"32","author":"Mina","year":"2018","journal-title":"Blood Rev"},{"issue":"17","key":"10.1016\/j.jtct.2025.06.002_bib0011","doi-asserted-by":"crossref","first-page":"1910","DOI":"10.1182\/blood-2017-10-810044","article-title":"Single-agent ibrutinib in treatment-naive and relapsed\/refractory chronic lymphocytic leukemia: a 5-year experience","volume":"131","author":"O'Brien","year":"2018","journal-title":"Blood"},{"issue":"26","key":"10.1016\/j.jtct.2025.06.002_bib0012","doi-asserted-by":"crossref","first-page":"2517","DOI":"10.1056\/NEJMoa1812836","article-title":"Ibrutinib Regimens versus Chemoimmunotherapy in Older Patients with Untreated CLL","volume":"379","author":"Woyach","year":"2018","journal-title":"N Engl J Med"},{"issue":"22","key":"10.1016\/j.jtct.2025.06.002_bib0013","doi-asserted-by":"crossref","first-page":"2095","DOI":"10.1056\/NEJMoa1900574","article-title":"Ibrutinib and Venetoclax for First-Line Treatment of CLL","volume":"380","author":"Jain","year":"2019","journal-title":"N Engl J Med"},{"issue":"30","key":"10.1016\/j.jtct.2025.06.002_bib0014","doi-asserted-by":"crossref","first-page":"2722","DOI":"10.1200\/JCO.19.00894","article-title":"Ibrutinib Plus Venetoclax in Relapsed\/Refractory Chronic Lymphocytic Leukemia: The CLARITY Study","volume":"37","author":"Hillmen","year":"2019","journal-title":"J Clin Oncol"},{"issue":"12","key":"10.1016\/j.jtct.2025.06.002_bib0015","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1056\/NEJMoa1713976","article-title":"Venetoclax-Rituximab in Relapsed or Refractory Chronic Lymphocytic Leukemia","volume":"378","author":"Seymour","year":"2018","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.jtct.2025.06.002_bib0016","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1056\/NEJMoa1315226","article-title":"Idelalisib and rituximab in relapsed chronic lymphocytic leukemia","volume":"370","author":"Furman","year":"2014","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.jtct.2025.06.002_bib0017","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1056\/NEJMoa2300696","article-title":"Pirtobrutinib after a Covalent BTK Inhibitor in Chronic Lymphocytic Leukemia","volume":"389","author":"Mato","year":"2023","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.jtct.2025.06.002_bib0018","first-page":"10","article-title":"Cancer statistics, 2025","volume":"75","author":"Siegel","year":"2025","journal-title":"CA Cancer J Clin"},{"issue":"12","key":"10.1016\/j.jtct.2025.06.002_bib0019","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1016\/j.bbmt.2016.09.013","article-title":"Clinical Practice Recommendations for Use of Allogeneic Hematopoietic Cell Transplantation in Chronic Lymphocytic Leukemia on Behalf of the Guidelines Committee of the American Society for Blood and Marrow Transplantation","volume":"22","author":"Kharfan-Dabaja","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"issue":"2","key":"10.1016\/j.jtct.2025.06.002_bib0020","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1182\/blood.2021014960","article-title":"Long-term outcomes for ibrutinib-rituximab and chemoimmunotherapy in CLL: updated results of the E1912 trial","volume":"140","author":"Shanafelt","year":"2022","journal-title":"Blood"},{"issue":"26","key":"10.1016\/j.jtct.2025.06.002_bib0021","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma","volume":"377","author":"Neelapu","year":"2017","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.jtct.2025.06.002_bib0022","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1056\/NEJMoa1804980","article-title":"Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma","volume":"380","author":"Schuster","year":"2019","journal-title":"N Engl J Med"},{"issue":"10254","key":"10.1016\/j.jtct.2025.06.002_bib0023","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/S0140-6736(20)31366-0","article-title":"Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study","volume":"396","author":"Abramson","year":"2020","journal-title":"Lancet"},{"issue":"8","key":"10.1016\/j.jtct.2025.06.002_bib0024","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1056\/NEJMoa1103849","article-title":"Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia","volume":"365","author":"Porter","year":"2011","journal-title":"N Engl J Med"},{"issue":"10402","key":"10.1016\/j.jtct.2025.06.002_bib0025","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1016\/S0140-6736(23)01052-8","article-title":"Lisocabtagene maraleucel in chronic lymphocytic leukaemia and small lymphocytic lymphoma (TRANSCEND CLL 004): a multicentre, open-label, single-arm, phase 1-2 study","volume":"402","author":"Siddiqi","year":"2023","journal-title":"Lancet"},{"issue":"10","key":"10.1016\/j.jtct.2025.06.002_bib0026","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1016\/j.jtct.2023.07.002","article-title":"Updated indications for immune effector cell therapy: 2023 Guidelines from the American Society for Transplantation and Cellular Therapy","volume":"29","author":"Kanate","year":"2023","journal-title":"Transplant Cell Ther"},{"issue":"Supplement 1","key":"10.1016\/j.jtct.2025.06.002_bib0027","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1182\/blood-2024-200339","volume":"144","author":"Wierda","year":"2024","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.jtct.2025.06.002_bib0028","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1111\/j.1365-2141.2007.06801.x","article-title":"Risk factors for development of a second lymphoid malignancy in patients with chronic lymphocytic leukaemia","volume":"139","author":"Maddocks-Christianson","year":"2007","journal-title":"Br J Haematol"},{"issue":"12","key":"10.1016\/j.jtct.2025.06.002_bib0029","doi-asserted-by":"crossref","first-page":"3391","DOI":"10.1182\/blood-2010-09-302174","article-title":"The genetics of Richter syndrome reveals disease heterogeneity and predicts survival after transformation","volume":"117","author":"Rossi","year":"2011","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.jtct.2025.06.002_bib0030","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.1016\/j.bbmt.2016.06.025","article-title":"Hematopoietic Cell Transplantation for Richter Syndrome","volume":"22","author":"El-Asmar","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"issue":"1","key":"10.1016\/j.jtct.2025.06.002_bib0031","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.hemonc.2020.05.002","article-title":"Allogeneic hematopoietic cell transplantation is an effective treatment for patients with Richter syndrome: A systematic review and meta-analysis","volume":"14","author":"Aulakh","year":"2021","journal-title":"Hematol Oncol Stem Cell Ther"},{"issue":"10","key":"10.1016\/j.jtct.2025.06.002_bib0032","doi-asserted-by":"crossref","first-page":"1958","DOI":"10.1182\/bloodadvances.2022008790","article-title":"A phase 2 study of nivolumab combined with ibrutinib in patients with diffuse large B-cell Richter transformation of CLL","volume":"7","author":"Jain","year":"2023","journal-title":"Blood Adv"},{"issue":"10","key":"10.1016\/j.jtct.2025.06.002_bib0033","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1016\/S1470-2045(24)00396-6","article-title":"Atezolizumab, venetoclax, and obinutuzumab combination in Richter transformation diffuse large B-cell lymphoma (MOLTO): a multicentre, single-arm, phase 2 trial","volume":"25","author":"Tedeschi","year":"2024","journal-title":"Lancet Oncol"},{"issue":"18","key":"10.1016\/j.jtct.2025.06.002_bib0034","doi-asserted-by":"crossref","first-page":"3528","DOI":"10.1182\/bloodadvances.2021004865","article-title":"Autologous and allogeneic hematopoietic cell transplantation for diffuse large B-cell lymphoma-type Richter syndrome","volume":"5","author":"Herrera","year":"2021","journal-title":"Blood Adv"},{"issue":"11","key":"10.1016\/j.jtct.2025.06.002_bib0035","first-page":"3566","article-title":"Anti-CD19 chimeric antigen receptor T-cell therapy has less efficacy in Richter transformation than in <I>de novo<\/I>large B-cell lymphoma and transformed low-grade B-cell lymphoma","volume":"109","author":"Benjamini","year":"2024","journal-title":"Haematologica"},{"issue":"16_suppl","key":"10.1016\/j.jtct.2025.06.002_bib0036","doi-asserted-by":"crossref","first-page":"7010","DOI":"10.1200\/JCO.2024.42.16_suppl.7010","article-title":"Real-world outcomes of lisocabtagene maraleucel (liso-cel) in patients (pt) with Richter transformation (RT) from the Center for International Blood and Marrow Transplant Research (CIBMTR)","volume":"42","author":"Winter","year":"2024","journal-title":"Journal of Clinical Oncology"},{"issue":"9","key":"10.1016\/j.jtct.2025.06.002_bib0037","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1038\/bmt.2012.71","article-title":"Comparing efficacy of reduced-toxicity allogeneic hematopoietic cell transplantation with conventional chemo-(immuno) therapy in patients with relapsed or refractory CLL: a Markov decision analysis","volume":"47","author":"Kharfan-Dabaja","year":"2012","journal-title":"Bone Marrow Transplant"},{"issue":"1","key":"10.1016\/j.jtct.2025.06.002_bib0038","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.beha.2016.08.001","article-title":"Current state of hematopoietic cell transplantation in CLL as smart therapies emerge","volume":"29","author":"Kharfan-Dabaja","year":"2016","journal-title":"Best Pract Res Clin Haematol"},{"issue":"Supplement 1","key":"10.1016\/j.jtct.2025.06.002_bib0039","doi-asserted-by":"crossref","first-page":"2178","DOI":"10.1182\/blood-2024-194156","article-title":"Single-Agent Ibrutinib Versus Allogeneic Hematopoietic Cell Transplantation for Patients With Relapsed\/Refractory Chronic Lymphocytic Leukemia\/Small Lymphocytic Lymphoma and del(17p)","volume":"144","author":"Awan","year":"2024","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.jtct.2025.06.002_bib0040","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1182\/blood-2018-04-785899","article-title":"How I treat refractory chronic graft-versus-host disease","volume":"133","author":"Sarantopoulos","year":"2019","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.jtct.2025.06.002_bib0041","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1038\/s41409-018-0401-4","article-title":"Bacterial blood stream infections (BSIs), particularly post-engraftment BSIs, are associated with increased mortality after allogeneic hematopoietic cell transplantation","volume":"54","author":"Ustun","year":"2019","journal-title":"Bone Marrow Transplant"},{"issue":"16","key":"10.1016\/j.jtct.2025.06.002_bib0042","doi-asserted-by":"crossref","first-page":"3977","DOI":"10.1182\/bloodadvances.2020001956","article-title":"Allogeneic stem cell transplantation for chronic lymphocytic leukemia in the era of novel agents","volume":"4","author":"Roeker","year":"2020","journal-title":"Blood Adv"},{"issue":"2","key":"10.1016\/j.jtct.2025.06.002_bib0043","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.hemonc.2017.11.001","article-title":"Reduced intensity is preferred over myeloablative conditioning allogeneic HCT in chronic lymphocytic leukemia whenever indicated: A systematic review\/meta-analysis","volume":"11","author":"Kharfan-Dabaja","year":"2018","journal-title":"Hematol Oncol Stem Cell Ther"},{"issue":"14","key":"10.1016\/j.jtct.2025.06.002_bib0044","doi-asserted-by":"crossref","first-page":"2438","DOI":"10.1182\/blood-2010-03-275420","article-title":"Allogeneic stem cell transplantation provides durable disease control in poor-risk chronic lymphocytic leukemia: long-term clinical and MRD results of the German CLL Study Group CLL3X trial","volume":"116","author":"Dreger","year":"2010","journal-title":"Blood"},{"issue":"9","key":"10.1016\/j.jtct.2025.06.002_bib0045","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1016\/j.bbmt.2014.05.020","article-title":"Outcomes of human leukocyte antigen-matched sibling donor hematopoietic cell transplantation in chronic lymphocytic leukemia: myeloablative versus reduced-intensity conditioning regimens","volume":"20","author":"Sobecks","year":"2014","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2025.06.002_bib0046","article-title":"Characteristics associated with response to lisocabtagene maraleucel (liso-cel) in patients (pts) with R\/R CLL\/SLL: exploratory analysis from TRANSCEND CLL 004","author":"Wierda","year":"2024","journal-title":"European Hematology Association"},{"issue":"5","key":"10.1016\/j.jtct.2025.06.002_bib0047","doi-asserted-by":"crossref","first-page":"1516","DOI":"10.1182\/blood-2010-09-308775","article-title":"Autologous hematopoietic stem cell transplantation in chronic lymphocytic leukemia: results of European intergroup randomized trial comparing autografting versus observation","volume":"117","author":"Michallet","year":"2011","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.jtct.2025.06.002_bib0048","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1038\/bmt.2011.117","article-title":"Autologous transplantation in CLL patients with B and C Binet stages: final results of the prospective randomized GOELAMS LLC 98 trial","volume":"47","author":"Brion","year":"2012","journal-title":"Bone Marrow Transplant"},{"issue":"4","key":"10.1016\/j.jtct.2025.06.002_bib0049","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1038\/bmt.2013.214","article-title":"Results of a randomized trial comparing high-dose chemotherapy plus Auto-SCT and R-FC in CLL at diagnosis","volume":"49","author":"Magni","year":"2014","journal-title":"Bone Marrow Transplant"},{"issue":"23","key":"10.1016\/j.jtct.2025.06.002_bib0050","doi-asserted-by":"crossref","first-page":"6109","DOI":"10.1182\/blood-2010-11-317073","article-title":"Autologous stem cell transplantation as a first-line treatment strategy for chronic lymphocytic leukemia: a multicenter, randomized, controlled trial from the SFGM-TC and GFLLC","volume":"117","author":"Sutton","year":"2011","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.jtct.2025.06.002_bib0051","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1038\/bmt.2015.69","article-title":"High-dose therapy and autologous hematopoietic cell transplantation as front-line consolidation in chronic lymphocytic leukemia: a systematic review","volume":"50","author":"Reljic","year":"2015","journal-title":"Bone Marrow Transplant"}],"container-title":["Transplantation and Cellular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636725012199?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636725012199?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,5]],"date-time":"2026-04-05T11:14:29Z","timestamp":1775387669000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666636725012199"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8]]},"references-count":51,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["S2666636725012199"],"URL":"https:\/\/doi.org\/10.1016\/j.jtct.2025.06.002","relation":{},"ISSN":["2666-6367"],"issn-type":[{"value":"2666-6367","type":"print"}],"subject":[],"published":{"date-parts":[[2025,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinical Practice Recommendations on the Role Of Allogeneic Hematopoietic Cell Transplantation and Chimeric Antigen Receptor T-Cell Therapy in Patients With Chronic Lymphocytic Leukemia on Behalf of the American Society for Transplantation and Cellular Therapy","name":"articletitle","label":"Article Title"},{"value":"Transplantation and Cellular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtct.2025.06.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Inc. on behalf of the American Society for Transplantation and Cellular Therapy.","name":"copyright","label":"Copyright"}]}}